The Federal Court ruled in favor of Janssen, stating their patent claims are valid and not obvious. A permanent injunction was issued against Teva's product until the patent's expiry. Teva appealed, Janssen cross-appealed. The court agreed with Janssen, dismissing Teva's appeal and granting the cross-appeal. The court determined that the patent covers prefilled syringes and dosage forms for paliperidone palmitate, finding the invention non-obvious. The judgment was amended to include the declaration of infringement by Teva's product.

No uploaded documents